Call for proposals: Early clinical development of new, promising TB vaccine candidates
TBVI has opened the following Call for proposals:
Deadline:
17:00 CEST, 11 September 2012
Problem
Tuberculosis (TB) remains an
urgent global health problem with 8.8 million new cases and 1.35
million deaths in 2010. An estimated one third of the world
population is latently infected with
Mycobacterium tuberculosis, and at risk of developing
TB. The dual pandemic of TB and HIV/AIDS and the increasing
emergence of (multi) drug-resistant strains severely aggravate
the problem and hamper current control strategies. The present
decline in incidence is insufficient to reach the global target
of elimination of TB in 2050 and new, more effective tools,
including new vaccines, are urgently required.
Scope
TBVI is a non-profit foundation that
contributes to the development of new TB vaccines accessible and
affordable to all people. TBVI aims to achieve this by
supporting research partners in universities, research
institutes and private companies that aim to develop new TB
vaccines from discovery to phase II clinical stage of
development.
Call
The current call for proposals
focuses on support for cGMP manufacturing, toxicity and safety
evaluation of new promising vaccine candidates, and/or support
for carrying out (first in human) phase I clinical trials.
Proposals must demonstrate complementarity and novelty of the
vaccine candidate as compared to the current global vaccine
pipeline. Vaccine candidates targeting HIV-uninfected
adolescents and young adults, and/or candidates with promise as
transmission blocking vaccine will have priority.
Available budget for this call: US$ 780,000. TBVI will contribute up to a maximum of 75% of the total funding (25% co-funding of total cost must be identified in the application)
Deadline for proposals: 17:00 CEST, 11 September 2012
Full text of the Call for proposals
Application form
TBVI Guidelines for applicants
TBVI
